Early post-approval results of gene therapy for RPE65-mediated retinal dystrophy with Luxturna (voretigene neparvovec) at Massachusetts Eye and Ear
2019
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI